Pharmacology of cancer chemotherapy in the older person

Clinics in Geriatric Medicine

Volumn 13, Issue 1, 1997, Pages 169-183

  Baker, S D ^a   Grochow, L B ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; BUSULFAN; CISPLATIN; METHOTREXATE;

AGED; ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; CANCER; CANCER CHEMOTHERAPY; CARDIOTOXICITY; DRUG ABSORPTION; DRUG DISTRIBUTION; GASTROINTESTINAL TOXICITY; HUMAN; LIVER METABOLISM; LUNG TOXICITY; NEPHROTOXICITY; NEUROTOXICITY; REVIEW;

EID: 0031057556     PISSN: 07490690     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0749-0690(18)30188-5     Document Type: Review

References (62)

1. Abigerges D. Chabot G.G. Armand J.-P. Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients J Clin Oncol 13 1995 210 221
2. Armitage J.O. Potter J.F. Aggressive chemotherapy for diffuse histiocytic lymphoma in the elderly: Increased complications with advancing age J Am Geriatr Soc 32 1984 269 273
3. Balducci L. Mowry K. Pharmacology and organ toxicity of chemotherapy in older patients Oncology 6 1992 62 68 (Suppl)
4. Balducci L. Parker M. Sexton W. Pharmacology of antineoplastic agents in the elderly patient Semin Oncol 16 1989 76 84
5. Begg C.B. Carbone P.P. Clinical trials and drug toxicity in the elderly Cancer 52 1983 1986 1992
6. Benjamin R.S. Rationale for the use of mitoxantrone in the older patient: Cardiac toxicity Semin Oncol 22 1 1995 11 13
7. Borkowski J.M. Duerr M. Donehower R.C. Relation between age and clearance rate of nine investigational anticancer drugs from phase I pharmacokinetic data Cancer Chemother Pharmacol 33 1994 493 496
8. Buzdar A. Marcus C. Smith T.L. Early and delayed cardiotoxicity of doxorubicin Cancer 55 1985 2761 2765
9. Christman K. Muss H.B. Case L.D. Chemotherapy of metastatic breast cancer in the elderly: The Piedmont Oncology Association Experience JAMA 268 1992 57 62
10. Cockcroft D.W. Gault M.H. Prediction of creatinine clearance from serum creatinine Nephron 16 1976 31 41
11. Cohen J. Pharmacokinetic changes in aging Am J Med 80 5A 1986 31 38
12. Conti J.A. Christman K. Cancer chemotherapy in the elderly J Clin Gastroenterol 21 1995 65 71
13. Danziger R.S. Tobin J.D. Becker L.C. The age-associated decline in glomerular filtration in healthy normotensive volunteers: Lack of relationship to cardiovascular performance J Am Geriatr Soc 38 1990 1127 1132
14. Dawling S. Crome P. Clinical pharmacokinetic considerations in the elderly: An update Clin Pharmacokinet 17 1989 236 263
15. DeSanto N.G. Anastasio P. Coppola S. Age-related changes in renal reserve and renal tubular function in healthy humans Child Nephrol Urol 11 1991 33 40
16. Durnas C. Loi C. Cusack B.J. Hepatic drug metabolism and aging Clin Pharmacokinet 19 1990 359 389
17. Egorin M. Cancer pharmacology in the elderly Semin Oncol 20 1993 43 49
18. Egorin M.J. Reyno L.M. Canetta R.M. Modeling toxicity and response in carboplatin-based combination chemotherapy Semin Oncol 21 12 1994 7 19
19. Ershler W.B. Balducci L. Treatment considerations for older patients with cancer In Vivo 8 1994 737 744
20. Evans W.E. Relling M.V. Clinical pharmacokinetics-pharmacodynamics of anticancer drugs Clin Pharmacokinet 16 1989 327 336
21. Feely J. Coakley D. Altered pharmacodynamics in the elderly Clin Geriatr Med 6 1990 269 283
22. Gelman R.S. Taylor S.G. Cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy in women more than 65 years old with advanced breast cancer: The elimination of age trends in toxicity by using doses based on creatinine clearance J Clin Oncol 2 1984 1404 1413
23. Ginsberg S.J. Comis R.L. The pulmonary toxicity of antineoplastic agents Semin Oncol 9 1982 34 51
24. Giovanazzi-Bannon S. Rademaker A. Lai G. Treatment tolerance of elderly cancer patients entered onto phase II clinical trials: An Illinois Cancer Center study J Clin Oncol 12 1994 2447 2452
25. Hrushesky J.M. Shimp W. Kennedy B.J. Lack of age-dependent cisplatin nephrotoxicity Am J Med 76 1984 579
26. Hutchins L.F. Lipschitz D.A. Cancer, clinical pharmacology, and aging Clin Geriatr Med 3 1987 483 502
27. Jackson D.V. Wells H.B. Atkins J.N. Amelioration of vincristine neurotoxicity by glutamic acid Am J Med 841 1988 2192 2195
28. Kintzel P.E. Dorr R.T. Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function Cancer Treat Rev 21 1995 33 64
29. Kristensen L.O. Weismann K. Hutters L. Renal function and the rate of disappearance of methotrexate from serum Eur J Clin Pharmacol 8 1975 439 444
30. Kokenberg E. Sonneveld P. Sizoo W. Cellular pharmacokinetics of daunorubicin: Relationships with the response to treatment in patients with acute myeloid leukemia J Clin Oncol 6 1988 802 812
31. Lalonde R.L. Pharmacodynamics Evans W.E. Applied Pharmacokinetics: Principles of Therapeutic Drug Monitoring, ed 3 1992 Applied Therapeutics, Inc. Vancouver WA 1 33
32. Leoni F. Ciolli S. Giuliani G. Attenuated-dose idarubicin in acute myeloid leukemia of the elderly: Pharmacokinetic study and clinical results Br J Haematol 90 1995 169 174
33. Leslie W.T. Chemotherapy in older cancer patients Oncology 6 1992 74 80
34. Lind M.J. Margison J.M. Cerny T. The effect of age on the pharmacokinetics of ifosfamide Br J Clin Pharmacol 30 1990 140 143
35. Lindeman R.D. Tobin J. Shock N.W. Longitudinal studies on the rate of decline in renal function with age J Am Geriatr Soc 33 1985 278 285
36. Lindeman R.D. Tobin J.D. Shock N.W. Association between blood pressure and the rate of decline in renal function with age Kidney International 26 1984 861 868
37. List A.F. Jacobs A. Biology and pathogenesis of the myelodysplastic syndromes Semin Oncol 19 1992 14 24
38. Lipschitz D.A. Age-related declines in hematopoietic reserve capacity Semin Oncol 22 l 1995 3 5
39. Mayerson M. Special pharmacokinetic considerations in the elderly Evans W.E. Applied Pharmacokinetics: Principles of Therapeutic Drug Monitoring, ed 2 1986 Applied Therapeutics, Inc Vancouver WA 244 246
40. Miller C.B. Piantadosi S. Vogelsang G.B. The impact of age on outcome of patients undergoing autologous bone marrow transplant J Clin Oncol 14 1996 1327 1332
41. Monfardini S. Sorio R. Kaye S. Should elderly cancer patients be entered in dose-escalation studies? Ann Oncol 5 1994 964 965
42. Monfardini S. Yancik R. Cancer in the elderly: Meeting the challenge of an aging population JNCI 7 1993 532 538
43. Peterson B.A. Pajak T.F. Cooper M.R. Effect of age on therapeutic response and survival in advanced Hodgkin's disease Cancer Treat Rep 66 1982 889 898
44. Petrelli N. Douglass H.O. Herrera L. The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: A prospective randomized phase III trial J Clin Oncol 7 1989 1419 1426
45. Phister J. Jue S.G. Cusack B.J. Problems in the use of anticancer drugs in the elderly Drugs 37 1989 551 565
46. Ratain M.J. Schilsky R.L. Conley B.A. Pharmacodynamics in cancer therapy J Clin Oncol 8 1990 1739 1753
47. Reece P.A. Stafford I. Russell J. Creatinine clearance as a predictor of ultrafilterable platinum disposition in cancer patients treated with cisplatin: Relationship between peak ultrafilterable platinum plasma levels and nephrotoxicity J Clin Oncol 5 1987 304 309
48. Robert J. Hoerni B. Age dependence of the early-phase pharmacokinetics of doxorubicin Cancer Res 43 1983 4467 4469
49. Rossman I. Clinical geriatrics, ed 2 1979 JB Lippincott Philadelphia 23 229
50. Rowe J.W. Andres R. Tobin J.D. The effect of age on creatinine clearance in men: A cross-sectional and longitudinal study J Gerontol 31 1976 155 163
51. Schiller J.H. Storer B. Berlin J. Amifostine, cisplatin, and vinblastine in metastatic non-small-cell lung cancer: a report of high response rates and prolonged survival J Clin Oncol 14 1996 1913 1921
52. Shank W. Balducci L. Recombinant hemopoietic growth factors: comparative hemopoietic response in younger and older subjects J Am Geriatr Soc 40 1992 151 154
53. Speyer J.L. Green M.D. Kramer E. Protective effect of the bispiperazinedione ICRF187 against doxorubicin induced cardiac toxicity in women with advanced breast cancer N Engl J Med 319 1988 745 752
54. Speyer J.L. Green M.D. Zeleniuch-Jacquotte A. ICRF-187 permits longer treatment with doxorubicin in women with breast cancer J Clin Oncol 10 1992 117 127
55. Tirelli U. Zagnoel V. Serraino D. Non-Hodgkin's lymphomas in 137 patients age 70 years or older: A retrospective European Organization for Research and Treatment of Cancer lymphoma group study J Clin Oncol 6 1988 1708 1713
56. Vermorken J.B. Nas der Vijgh W.J.F. Klein I. Pharmacokinetics of free platinum species following rapid, 3-h and 24-h infusions of cis-diamminedichloroplatinum (II) and its therapeutic implications Eur J Cancer Clin Oncol 18 1982 1069 1074
57. Vesell E.S. DeAngelo T.M. Katz I.R. Reproducibility of antipyrine half-lives in elderly subjects Clin Pharmacol Ther 54 1993 150 157
58. Wallace S. Whiting B. Factor affecting drug binding in plasma of elderly patients Br J Clin Pharmacol 3 1976 327 330
59. Vose J. Cytokine use in the older patient Semin Oncol 22 l 1995 6 8
60. Wei J.Y. Cardiovascular comorbidity in the older cancer patient Semin Oncol 22 1 1995 9 10
61. Yamamoto N. Tamura T. Maeda M. The influence of ageing on cisplatin pharmacokinetics in lung cancer patients with normal organ function Cancer Chemother Pharmacol 36 1995 102 106
62. Yuen G. Altered pharmacokinetics Clin Geriatr Med 6 1990 257 268